Log in

Relevant bibliographies by topics / 6]dec-3-en-9-one and tricyclo[5.2.1.02 / Journal articles

To see the other types of publications on this topic, follow the link: 6]dec-3-en-9-one and tricyclo[5.2.1.02.

Journal articles on the topic '6]dec-3-en-9-one and tricyclo[5.2.1.02'

Author: Grafiati

Published: 5 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic '6]dec-3-en-9-one and tricyclo[5.2.1.02.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Sabreen, A. Kamal. "In Vitro Antifunal Potential of Morganella morganii and Determination of its Chemical Composition by Gas ChromatographyMass Spectrometry." International Journal of Current Pharmaceutical Review and Research 8, no. 2 (2017): 99–113. https://doi.org/10.5281/zenodo.12677764.

Full text

Abstract:

Bioactives were analyzed using gas chromatography-mass spectroscopy (GC-MS) techniques, then the in vitroantibacterial and antifungal activity of the methanolic extract was evaluated. GC-MS analysis of Morganella morganiirevealed the existence of the Tricyclo[4.3.1.1(3.8)]undecan-1-amine, 3-Methoxybenzaldehyde semicarbazone,carboxaldehyde , 1-methyl-,oxime ,(Z)-(+), 1,5,5-Trimethyl-6-methylene-cyclohexene, 4-(2,5-Dihydro-3-methoxyphenyl)butylamine, Paromomycin , 9-Borabicyclo[3.31]nonane , 9-mercapto-, Benzenemethanol , 2-(2-aminopropoxy)-3-methyl, Acetamide , N-(6-acetylaminobenzothiazol-2-yl

APA, Harvard, Vancouver, ISO, and other styles

2

Sajjad Saad Zghair, Sahar Sarhan Thajeel, and Imad Hadi Hameed. "Characterization of antimicrobial secondary metabolites produced by Klebsiella pneumoniae and screening of its bioactive natural compounds using gas chromatography-mass spectrometry (GC-MS)." International Journal of Life Science Research Archive 5, no. 1 (2023): 076–89. http://dx.doi.org/10.53771/ijlsra.2023.5.1.0071.

Full text

Abstract:

Microbial secondary metabolites are low molecular mass products with unusual structures. The structurally diverse metabolites show a variety of biological activities like antimicrobial agents. Thirty nine bioactive compounds were identified in the methanolic extract of Klebsiella pneumoniae. GC-MS analysis of Klebsiella pneumoniae revealed the existence of the Tricyclo[4.3.1.1(3.8)]undecan-1-amine, 3-Methoxybenzaldehyde semicarbazone, carboxaldehyde , 1-methyl-,oxime ,(Z)-(+), 1,5,5-Trimethyl-6-methylene-cyclohexene, 4-(2,5-Dihydro-3-methoxyphenyl)butylamine, Paromomycin , 9-Borabicyclo[3.31]n

APA, Harvard, Vancouver, ISO, and other styles

3

Jenan, Mohammed Ubaid, Jawad Kadhim Mohanad, and Hadi Hameed Imad. "Study of Bioactive Methanolic Extract of Camponotus fellah Using Gas Chromatography – Mass Spectrum." International Journal of Toxicological and Pharmacological Research 8, no. 6 (2017): 434–39. https://doi.org/10.5281/zenodo.12770188.

Full text

Abstract:

GC-MS analysis of <em>Camponotus fellah</em> revealed the existence of the  Cyclopentaneacetaldehyde ,2-formyl-3-methyl-α-methylene-, Cyclohexene, 1-methyl-5-(1-methylethenyl)-,(R)-, Bicyclo[5.1.0]octane, 8-methylene-,5-Methyl-6-phenyltetrahydro – 1,3-oxazine-2-thione, Decane, 1-Heptanol, 2-propyl, Octane, -4-methyl, Cyclopentanol, 2-(2-propynyloxy)-, trans-, Hydroxylamine, O-decyl, Trans-2-Ethyl-2-hexen-1-ol, Cyclopropene,1-methyl-3-(2-methylcyclopropyl)-, 10-methyl-endo-tricyclo[5.2.1.0(2.6)]decane, Undecen-1-yne, (Z, Exo-Norbornyl propionate, 5,8,10-Undecatrien-3-

APA, Harvard, Vancouver, ISO, and other styles

4

Blanchfield, JT, DJ Brecknell, IM Brereton, MJ Garson, and DD Jones. "Caloundrin B and Funiculatin A: New Polypropionates From Siphonariid Limpets." Australian Journal of Chemistry 47, no. 12 (1994): 2255. http://dx.doi.org/10.1071/ch9942255.

Full text

Abstract:

Two new polypropionates, caloundrin B (11), systematic name (1″R,2R,3″R,4R,5S,5″R,6S,-7″R,8″S,9″S,10″R)-2-(6′-ethyl-3′,5′-dimethyl-4′-oxopyran-2′-yl)-6-(5″-ethyl-7″-hydroxy-8″,9″,10″-trimethyl-2″,4″,6″-trioxatricyclo[3.3.1.13,7]dec-3″-yl)-5-hydroxy-4-methylheptan-3-one, and funiculatin A (12), systematic name (2ξ,1′S,4R,5′S,6′S)-2-(1′-ethyl-4′,6′,8′-trimethyl-2𔈀,9′-dioxabicyclo[3.3.1]nona-3′,7′-dien-3′-yl)-4,6-dimethylnon-6-en-3-one, have been isolated from Siphonaria zelandica and S. funiculata respectively. The structures of the new compounds were deduced by two-dimensional n.m.r. spectrosco

APA, Harvard, Vancouver, ISO, and other styles

5

Liu, Qi Mei, та Wan Xi Peng. "80°С-Based TD-GC/MS Analysis of Chemical Components from Branches of Cinnamomum camphora". Key Engineering Materials 480-481 (червень 2011): 466–71. http://dx.doi.org/10.4028/www.scientific.net/kem.480-481.466.

Full text

Abstract:

The analytical result by 80°С-based TD-GC/MS showed that 65 peaks were obtained from the helium volatiles from the fresh branches of Cinnamomum camphora and 60 chemical compounds were identified. The results showed that the main components were as: 1,3-Benzodioxole, 5-(2-propenyl)- (12.629%), Tricyclo[2.2.1.0(2,6)]heptane, 1,7-dimethyl-7-(4-methyl-3-pentenyl)-, (-)- (10.302%), 3-Cyclohexene-1-methanol, .alpha.,.alpha.4-trimethyl- (9.084%), Bicyclo[2.2.1] heptan-2-one, 1,7,7-trimethyl-, (1R)- (7.406%), Nerolidol (6.695%), Bicyclo[2.2.1]heptane, 2-methyl-3-methylene-2-(4-methyl-3-pentenyl)-, (1S

APA, Harvard, Vancouver, ISO, and other styles

6

Coll, JC, and AD Wright. "Tropical Marine Algae. III. New Sesquiterpenes From Laurencia majuscula (Rhodophyta, Rhodophyceae, Ceramiales, Rhodomelaceae)." Australian Journal of Chemistry 42, no. 9 (1989): 1591. http://dx.doi.org/10.1071/ch9891591.

Full text

Abstract:

The isolation and structural elucidation of new sesquiterpenes from Laurencia majuscula, collected from Zoe Bay, Hinchinbrook Island, North Queensland, are reported. One collection contained the novel triquinane derivative: (1S*,2S*,3S*,5S*,8S*,9S*)- tricyclo [6.3.0.01.5] undecan-2-ol (3), and four halogenated chamigrene derivatives: the known 1(15)Z compound (4) and the new (1(15)E,2Z,4S,8R,9S)-8,15-dibromochamigra-1(15,2,1112-trien-9-ol (5), the known isoobtusadiene (6) and the new metabolite (1S,2S,4R,8R,9S)-1-chloro-2,8-dibromochamigr-11(12)-en-9-ol (7). A second collection afforded the sa

APA, Harvard, Vancouver, ISO, and other styles

7

Zhang, Zhong Feng, and Xian Yan Zhou. "GC/MS Analysis on Benzene/Alcohol Extractives of Manglietia Glauca Leavies for Biomedicine Engineering." Advanced Materials Research 213 (February 2011): 475–78. http://dx.doi.org/10.4028/www.scientific.net/amr.213.475.

Full text

Abstract:

Manglietia glauca leavies has a strong bactericidal Manglietia health capacity. However Manglietia glauca leavies are still underutilized and hence wasted. In order to better utilize Manglietia glauca leavies resources, the biomedicine resource of benzene/alcohol extractives from Manglietia glauca leavies were analyzed by GC/MS. Relative content of each component was determined by area normalization. The main ingredients of benzene/alcohol extractives of Manglietia glauca leavies were tritriacontane(4.84%), 9-octadecyne(4.19%), ethyl alcohol(3.23%), 2-furanmethanamine, tetrahydro-(3.1%), .beta

APA, Harvard, Vancouver, ISO, and other styles

8

McNamara, Mairead Geraldine, Jayne Swain, Zoe Craig, et al. "NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC)." Journal of Clinical Oncology 40, no. 16_suppl (2022): 4005. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.4005.

Full text

Abstract:

4005 Background: The prognosis for pts with PD-EP-NEC is poor. A recognised first-line (1L) treatment for advanced disease is etoposide/platinum-based chemotherapy; there is no standard second-line (2L) treatment (area of unmet need). Methods: This was a multi-centre, randomised (1:1), phase II trial of IV nal-IRI (70mg/m2 free base)/5-FU (2400 mg/m2)/folinic acid, Q14 days (ARM A), or IV docetaxel (75mg/m2), Q21 days (ARM B), as 2L therapy in a planned 102 pts with progressive PD-EP-NEC, aimed at selecting a treatment for continuation to a phase III trial. Pts with histologically-confirmed PD

APA, Harvard, Vancouver, ISO, and other styles

9

McNamara, Mairead Geraldine, Jayne Swain, Zoe Craig, et al. "NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC)." Journal of Clinical Oncology 40, no. 16_suppl (2022): 4005. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.4005.

Full text

Abstract:

4005 Background: The prognosis for pts with PD-EP-NEC is poor. A recognised first-line (1L) treatment for advanced disease is etoposide/platinum-based chemotherapy; there is no standard second-line (2L) treatment (area of unmet need). Methods: This was a multi-centre, randomised (1:1), phase II trial of IV nal-IRI (70mg/m2 free base)/5-FU (2400 mg/m2)/folinic acid, Q14 days (ARM A), or IV docetaxel (75mg/m2), Q21 days (ARM B), as 2L therapy in a planned 102 pts with progressive PD-EP-NEC, aimed at selecting a treatment for continuation to a phase III trial. Pts with histologically-confirmed PD

APA, Harvard, Vancouver, ISO, and other styles

10

Stansly, P. A., and J. M. Conner. "Control of Southern Armyworm with Bacillus Thuringiensis in Staked Tomato, Fall 1994." Arthropod Management Tests 21, no. 1 (1996): 191. http://dx.doi.org/10.1093/amt/21.1.191.

Full text

Abstract:

Abstract Greenhouse raised tomato seedings “Florasette” were planted 8 Sep. 1994, 18 inches within the row on six subirrigated beds, 240 ft long, 32 ft wide on 6 ft centers. Beds had been fumigated with methyl bromide + chloropicrin 67/33 at a rate of 2201b/acre and mulched with whiteside polyethylene. Each of 4, 125 ft blocks was divided into 4, 3-row plots 25 ft long plus 2.5 ft walkways. Plants were sprayed weekly with an alternating combination of Maneb 80 WP at 1 lb/acre plus Kocide 101 at 31b/acre and Bravo 720 at 1.5 pt/acre for disease control. Plants were inoculated on 5 Oct with beet

APA, Harvard, Vancouver, ISO, and other styles

11

Tolaney, Sara, Paolo Tarantino, Noah Graham, et al. "Abstract PD18-02: Adjuvant Paclitaxel and Trastuzumab Trial (APT) for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive (HER2+) Breast Cancer: final 10-year analysis." Cancer Research 83, no. 5_Supplement (2023): PD18–02—PD18–02. http://dx.doi.org/10.1158/1538-7445.sabcs22-pd18-02.

Full text

Abstract:

Abstract Background: The APT trial evaluated the activity of adjuvant paclitaxel and trastuzumab (TH) among patients with small, node negative HER2+ breast cancer. This regimen showed a 7-year invasive disease-free survival (iDFS) of 93%, a recurrence-free interval (RFI) of 97.5% with only four (1.0%) distant recurrences, and a 7-year overall survival (OS) of 95%. In this end-of-study analysis, we report the survival outcomes at 10 years and assess the role of HER2DX testing in predicting long-term outcomes with adjuvant TH. Methods: APT was a single-arm multicenter investigator-initiated phas

APA, Harvard, Vancouver, ISO, and other styles

12

Fernandez, Aileen I., Matthew Liu, Andrew Bellizzi, et al. "Abstract P1-02-02: Examination of low Her2 expression in breast cancer." Cancer Research 82, no. 4_Supplement (2022): P1–02–02—P1–02–02. http://dx.doi.org/10.1158/1538-7445.sabcs21-p1-02-02.

Full text

Abstract:

Abstract Introduction: Antibody-drug conjugates (ADC) are designed to effectively deliver cytotoxic agents directly to malignant cells. Trastuzumab deruxtecan (Tdx), an ADC of trastuzumab, an enzyme-cleavable linker, and a cytotoxic topoisomerase I inhibitor, has been shown to have antitumor activity in patients with breast cancer with low levels of HER2. However, current companion diagnostic tests for HER2-targetting therapies, immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH), were optimized for high (gene amplified) levels of HER2. We hypothesize that the current commo

APA, Harvard, Vancouver, ISO, and other styles

13

Spring, Laura M., Lauren Scarpetti, Andrzej Niemierko, et al. "Abstract P1-14-02: Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER, part 1)." Cancer Research 82, no. 4_Supplement (2022): P1–14–02—P1–14–02. http://dx.doi.org/10.1158/1538-7445.sabcs21-p1-14-02.

Full text

Abstract:

Abstract Background: CDK 4/6 inhibitors have demonstrated substantial efficacy in treating ER+/HER2- metastatic breast cancer. Therefore, there is great interest in exploring their ability to reduce recurrence risk in early breast cancer. However, conflicting results were observed in the large adjuvant phase 3 clinical trials investigating combination of endocrine therapy and CDK 4/6 inhibitor (PALLAS, MONARCH-E). While these adjuvant clinical trials evaluated upfront use of CDK 4/6 inhibitor, the optimal timing of adding CDK 4/6 inhibitor for HR+/HER2- breast cancer remains unknown. We conduc

APA, Harvard, Vancouver, ISO, and other styles

14

Khan, Sohail, Saira Khawaja, Yousef Sharaiha, Asma Munir, and Anita Huws. "Abstract PO3-02-09: Breast cancer in women under the age of 40 years.A south Wales UK reflection on incidence, tumour biology and outcomes over 10 years." Cancer Research 84, no. 9_Supplement (2024): PO3–02–09—PO3–02–09. http://dx.doi.org/10.1158/1538-7445.sabcs23-po3-02-09.

Full text

Abstract:

Abstract Introduction: The incidence of breast cancer in the under 40-year-old age group is approximately 7% (Anders et al., 2009). Studies suggests that the management of Breast cancer in adolescent and young women is more challenging, with this age group under-represented in clinical trials. We investigated the management and outcomes of a cohort of 98 patients seen between 2013 and 2023 in the Hywel Dda NHS University Health Board, Wales, UK. Methods: A retrospective review was performed. Demographic, surgical and outcome data for patients under the age of 40 years was collated and analysed

APA, Harvard, Vancouver, ISO, and other styles

15

Puskulluoglu, Miroslawa, Malgorzata Pieniazek, Joanna Streb, et al. "Abstract P4-05-02: Strategies for premedication and neutropenia prophylaxis in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights." Clinical Cancer Research 31, no. 12_Supplement (2025): P4–05–02—P4–05–02. https://doi.org/10.1158/1557-3265.sabcs24-p4-05-02.

Full text

Abstract:

Abstract Background: Sacituzumab govitecan (SG) is approved for use in the second line and beyond for advanced triple-negative breast cancer (TNBC), improving survival outcomes compared to standard chemotherapy. As demonstrated by the ASCENT trial and real-world data, typical adverse events (AEs) of SG include myelosuppression, diarrhea, nausea, vomiting, or hepatic toxicity. Premedication strategies should address these AEs. In patients with specific AEs, additional prophylaxis, such as granulocyte colony-stimulating factor (G-CSF), may be required. The purpose of this study was to evaluate p

APA, Harvard, Vancouver, ISO, and other styles

16

Damodaran, Senthil, Diane Liu, Jill Schwartz, et al. "Abstract P3-02-03: A phase Ib trial of bintrafusp alfa and eribulin in patients with metastatic triple negative breast cancer (TNBC)." Cancer Research 83, no. 5_Supplement (2023): P3–02–03—P3–02–03. http://dx.doi.org/10.1158/1538-7445.sabcs22-p3-02-03.

Full text

Abstract:

Abstract Background: Metastatic TNBC is an aggressive breast cancer subtype with poor prognosis and limited systemic therapy options. While pembrolizumab in combination with chemotherapy is approved for PD-L1 positive TNBC, limited immunotherapy options exist for patients with progressive and/or PD-L1 negative disease. TGFβ released by cancer cells and stromal fibroblasts attenuates the intrinsic antitumor potential of immune cells within the tumor microenvironment mediating resistance to immunotherapy. Consequently, inhibition of TGFβ signaling could potentially enhance antitumor responses to

APA, Harvard, Vancouver, ISO, and other styles

17

Dhakal, Ajay, Ruth O’Regan, Carla Falkson, et al. "Abstract OT1-10-02: Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling." Cancer Research 83, no. 5_Supplement (2023): OT1–10–02—OT1–10–02. http://dx.doi.org/10.1158/1538-7445.sabcs22-ot1-10-02.

Full text

Abstract:

Abstract Background: Development of brain metastasis (BM) portends poor prognosis in patients (pts) with metastatic breast cancer (MBC) mainly due to lack of systemic therapy with strong activity in CNS. While survival in HER2+ BC BMs has improved due to development of various HER2 therapies with activity against BM, outcome for HER2- BC BMs remains dismal. A novel assay (CELsignia) which measures underlying HER2 signal (HS) of live cancer cells in response to HER2 agonists & antagonists showed that about 25% of BC deemed HER2- by standard methods have underlying abnormal HS. Preclinical d

APA, Harvard, Vancouver, ISO, and other styles

18

Hurvitz, Sara, Fabrice André, Massimo Cristofanilli, et al. "Abstract PO2-20-02: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)." Cancer Research 84, no. 9_Supplement (2024): PO2–20–02—PO2–20–02. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-20-02.

Full text

Abstract:

Abstract Patients who receive frontline CDK4/6 inhibitor (CDK4/6i) therapy eventually experience disease progression. Resistance to CDK4/6i is likely a transient adaptive mechanism that may be reversed by inhibition of the PI3K/mTOR pathway. Thus, combination of CDK4/6i and PI3K/mTORi after disease progression on CDK4/6i could restore sensitivity to CDK4/6i and prevent activation of the PI3K/mTOR pathway. This hypothesis was evaluated in a Phase 1b study (Layman SABCS 2021) of gedatolisib (geda), a potent inhibitor of PI3K and mTOR. Subjects with HR+/HER2- ABC treated with prior CDK4/6i receiv

APA, Harvard, Vancouver, ISO, and other styles

19

Calvo Caravaca, Alfonso Luis, and María Pilar Canedo Arrillaga. "Casos escogidos de Derecho antitrust europeo." Estudios de Deusto 54, no. 1 (2014): 285. http://dx.doi.org/10.18543/ed-54(1)-2006pp285-373.

Full text

Abstract:

Caso N.º 1. Ententes: Dec.Com. 7 abril 2004, Société Air France/Alitalia Linee Aeree Italiane SpA, DO L 362 de 9 diciembre 2004 Caso N.º 2. Ententes: STJCE 29 abril 2004, C-359/01 P, British Sugar plc/Comisión Caso N.º 3. Ententes: STPI de 29 de abril de 2004, Tokai carbón Co. Ltd y otros/Comisión de las Comunidades Europeas As. T-236/01, T-239/01, T-244/01, T-245/01, T-246/01, T-251/01 y T-252/01 Caso N.º 4. Ententes: Sentencia del Tribunal de Primera Instancia 15 junio 2005, Graphites spéciaux, As. T-71/03, T-74/03, T-87/03 y T-91/03 Caso N.º 5. Ententes: STPI 8 julio 2004, Mannesmannröhren-

APA, Harvard, Vancouver, ISO, and other styles

20

Shah, Zunairah, Arya Mariam Roy, Varsha Gupta, et al. "Abstract P2-02-24: Evaluating ChatGPT as an educational resource for patients with Breast cancer: A preliminary investigation." Clinical Cancer Research 31, no. 12_Supplement (2025): P2–02–24—P2–02–24. https://doi.org/10.1158/1557-3265.sabcs24-p2-02-24.

Full text

Abstract:

Abstract Introduction: Breast cancer (BC) is the most commonly diagnosed cancer among women in the United States, representing about 30% of new cases annually. Patients with BC encounter various challenges, such as understanding the disease, exploring treatment options, managing prognosis, coping with side effects, and accessing supportive care. Educating patients is crucial for empowering them to make informed healthcare decisions. With the evolution of artificial intelligence (AI), there is potential to leverage these technologies for patient education. ChatGPT, an AI-based language model, i

APA, Harvard, Vancouver, ISO, and other styles

21

Waks, Adrienne, Hillary Heiling, Paula Pohlmann, et al. "Abstract LB1-02: MARGOT/TBCRC052: A randomized phase II trial comparing neoadjuvant paclitaxel/margetuximab/pertuzumab (TMP) vs paclitaxel/trastuzumab/pertuzumab (THP) in patients (pts) with stage II-III HER2+ breast cancer." Clinical Cancer Research 31, no. 12_Supplement (2025): LB1–02—LB1–02. https://doi.org/10.1158/1557-3265.sabcs24-lb1-02.

Full text

Abstract:

Abstract Background: Margetuximab combined with chemotherapy modestly improves outcomes compared to trastuzumab plus chemotherapy in pts with heavily pre-treated HER2+ metastatic breast cancer. The efficacy of margetuximab for pts with newly diagnosed HER2+ early breast cancer (EBC) is unknown. Methods: Eligible pts had previously untreated stage II-III HER2+ EBC, any hormone receptor (HR) status, and CD16A genotype FF or FV by central testing. Pts were randomized 2:1 to neoadjuvant TMP or THP for 4 cycles (weekly T x12; q3wk MP or HP x4). ER status and baseline clinical stage were stratificat

APA, Harvard, Vancouver, ISO, and other styles

22

Fostira, Florentia, Dimitrios Nasikas, Paraskevi Apostolou, et al. "Abstract P6-02-10: Prevalence of breast cancer predisposing variants in patients with breast carcinoma in situ." Cancer Research 83, no. 5_Supplement (2023): P6–02–10—P6–02–10. http://dx.doi.org/10.1158/1538-7445.sabcs22-p6-02-10.

Full text

Abstract:

Abstract Background. Carcinoma in situ (CIS) of the breast is a non-obligatory pre-malignant breast lesion and a highly suspected precursor of invasive cancer. Although the selection criteria for referral to genetic testing are well established for patients diagnosed with invasive breast cancer, these are not clear for patients diagnosed with CIS. Our goal is to assess the prevalence of predisposing pathogenic variants in key genes, as well as to describe factors in patients with CIS that might be associated with genetic predisposition. Methods. A total of 267 patients solely diagnosed with CI

APA, Harvard, Vancouver, ISO, and other styles

23

Merlini, Giampaolo, Vaishali Sanchorawala, Zonder A. Jeffrey, et al. "Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)." Blood 124, no. 21 (2014): 3450. http://dx.doi.org/10.1182/blood.v124.21.3450.3450.

Full text

Abstract:

Abstract Background Systemic AL amyloidosis is a life-threatening disease with limited treatment options. Response criteria have been recently updated and retrospectively validated (Palladini et al, J Clin Oncol 2012). Hematologic response (suppression of FLCs) has been shown to predict for both organ response and survival (ibid). Preliminary results from the present phase 1 study (NCT01318902) regarding the safety, tolerability, and maximum tolerated dose (MTD) of ixazomib (the first oral PI to be investigated in the clinic) in RRAL were reported previously (Merlini et al, ASH 2012). At that

APA, Harvard, Vancouver, ISO, and other styles

24

Gion, María, Manuel Ruiz-Borrego, Isabel Blancas, et al. "Abstract P1-02-06: Efficacy analysis & updated safety from the phase 2 PRIMED study of prophylactic granulocyte-colony stimulating factor (G-CSF) & loperamide for patients (pts) with HER2-negative advanced breast cancer (ABC) treated w/ sacituzumab govitecan (SG)." Clinical Cancer Research 31, no. 12_Supplement (2025): P1–02–06—P1–02–06. https://doi.org/10.1158/1557-3265.sabcs24-p1-02-06.

Full text

Abstract:

Abstract Background SG is a Trop-2 directed antibody drug conjugate that has shown a statistically significant and clinically meaningful overall survival benefit for pts with HER2- ABC in two phase III trials. The most common SG-related adverse events (AEs) were neutropenia and diarrhea, which frequently led to treatment modifications. The PRIMED trial previously demonstrated that primary prophylactic administration of G-CSF and loperamide resulted in a clinically meaningful reduction of neutropenia and diarrhea during the first two treatment cycles. Herein we report the extended safety follow

APA, Harvard, Vancouver, ISO, and other styles

25

Zhang, Lina, Chao Yang, Jie Ma, et al. "Abstract PO2-02-05: CDK4/6 inhibitor dalpiciclib combined with letrozole as neoadjuvant therapy in postmenopausal patients with hormone receptor-positive, HER2-negative stage II-III breast cancer: a single-arm exploratory trial." Cancer Research 84, no. 9_Supplement (2024): PO2–02–05—PO2–02–05. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-02-05.

Full text

Abstract:

Abstract Background: Patients with HR-positive, HER2-negative breast cancer respond poorly to neoadjuvant chemotherapy. The phase 3 DAWNA-1 and DAWNA-2 studies have proved that adding dalpiciclib (a CDK4/6 inhibitor) to endocrine therapy can significantly improve progression-free survival in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer. However, the evidence of dalpiciclib in the neoadjuvant setting is limited. This study aimed to explore the efficacy and safety of dalpiciclib plus letrozole as neoadjuvant therapy in in patients with HR-positive, HER2-nega

APA, Harvard, Vancouver, ISO, and other styles

26

Kim, Jee Hung, Soong June Bae, Sung Gwe Ahn, et al. "Abstract PO5-02-09: Discordance of the PAM50 intrinsic subtypes with the immunohistochemistry-based subtypes in HER2-negative early breast cancer treated with neoadjuvant chemotherapy." Cancer Research 84, no. 9_Supplement (2024): PO5–02–09—PO5–02–09. http://dx.doi.org/10.1158/1538-7445.sabcs23-po5-02-09.

Full text

Abstract:

Abstract Background The PAM50 (Prosigna Breast Cancer Gene Signature Assay) can be used to assess the expression levels of 50 genes in early breast cancer biopsies, including formalin-fixed paraffin-embedded (FFPE) tissue from human epidermal growth factor receptor 2 (HER2)-negative patients. However, there is currently no practical molecular assay for intrinsic subtype in real-world practice that addresses the problems of cost and run-time. Methods In the phase 2 HER2E-PAM/PAMILIA study (NCT04817540), we prospectively analyzed molecular subtyping through the PAM50 test in low HER2 (HER2 IHC 1

APA, Harvard, Vancouver, ISO, and other styles

27

Cavalcante, Francisco Pimentel, Felipe Zerwes, Alessandra Souza, et al. "Abstract PO4-23-02: Blue Dye-Only for Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients with Initially Node-positive Breast Cancer." Cancer Research 84, no. 9_Supplement (2024): PO4–23–02—PO4–23–02. http://dx.doi.org/10.1158/1538-7445.sabcs23-po4-23-02.

Full text

Abstract:

Abstract Importance: Randomized trials evaluated the false negative rate (FNR) of sentinel lymph node biopsy (SLNB) in initially node-positive (cN1/2) breast cancer (BC) patients who downstaged after neoadjuvant chemotherapy (NAC): the studies were negative, as they found FNR above 10%. However, the FNR was adequate when the lymph node was marked with a clip before NAC or at least 3 lymph nodes were removed. SLNB using a combination of blue dye and a radiotracer (Technetium-99) was encouraged to facilitate identification and maximize SLNB results in this scenario. However, radiotracer is unava

APA, Harvard, Vancouver, ISO, and other styles

28

Azarnoush, Saba, Raphael Porcher, Regis Peffault de la Tour, et al. "Outcome of Busulfan and Fludarabine-Based Reduced Intensity Conditioning Regimen for Related and Unrelated HSCT in Fanconi Anemia Patients." Blood 118, no. 21 (2011): 1964. http://dx.doi.org/10.1182/blood.v118.21.1964.1964.

Full text

Abstract:

Abstract Abstract 1964 Rationale: HSCT is the only curative treatment for Fanconi Anemia (FA) pts with either bone marrow failure or MDS/Leukemia. Due to characteristic chromosomal instability, the poor outcome of FA pts transplanted after so-called conventional myelo-ablative conditioning regimen has been proved. Then, reduced-intensity conditionning regimen (RIC) has been considered for years as a model for allogeneic HSCT in FA pts. The use of fludarabine-based cond' regimen from about 2000 increased dramatically the overall survival of FA pts. Different Flu-based RIC were developed. Patien

APA, Harvard, Vancouver, ISO, and other styles

29

Dunn, Janet, Peter Donnelly, Nada Elbeltagi, et al. "Abstract GS03-02: Mammographic surveillance in early breast cancer patients aged 50 years or over: results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography." Cancer Research 84, no. 9_Supplement (2024): GS03–02—GS03–02. http://dx.doi.org/10.1158/1538-7445.sabcs23-gs03-02.

Full text

Abstract:

Abstract Introduction: Annual surveillance mammograms for an unspecified period, after treatment for early breast cancer, are widely practised in USA and Europe and represent a significant healthcare cost. Current UK guidelines recommend annual mammograms up to 5 years, then reverts to 3 year screening without specified risk stratification. Further evidence is needed to determine the optimum frequency and duration of mammographic surveillance. Methods: A multi-centre, randomised controlled, phase III trial of annual mammography versus 2-yearly for conservation surgery and 3-yearly mammograms f

APA, Harvard, Vancouver, ISO, and other styles

30

Zhang, Jian, Xichun Hu, Qingyuan Zhang, et al. "Abstract P5-05-22: ARX788 for patients with HER2-positive advanced breast cancer: characterization, time course, and monitoring and management of adverse event from the phase III ACE-Breast-02 study." Clinical Cancer Research 31, no. 12_Supplement (2025): P5–05–22—P5–05–22. https://doi.org/10.1158/1557-3265.sabcs24-p5-05-22.

Full text

Abstract:

Abstract Background: ARX788 is a non-natural amino acid site-specific conjugated ADC with high homogeneity and stability. In the ACE-Breast-02 primary analysis, ARX788 demonstrated significantly prolonged PFS by blinded independent central review in patients with HER2-positive advanced breast cancer (HR 0.64, 95%CI, 0.49-0.82; p=0.0006). Here we report the detailed safety analysis and management of ocular and interstitial lung disease (ILD). Methods: 441 eligible patients were randomized 1:1 to receive ARX788 or lapatinib plus capecitabine. Safety analysis was conducted until the data cutoff (

APA, Harvard, Vancouver, ISO, and other styles

31

Roozeboom, Fred, Jonas Sundqvist, Dmitry B. Suyatin, and Kuniyuki Kakushima. "Seiichi Iwamatsu, the Inventor of Atomic Layer Etching: The Conception of Cycled Exposures of Silicon to Halogens and Pulses of Heat, Ions, and More." ECS Meeting Abstracts MA2024-02, no. 30 (2024): 5068. https://doi.org/10.1149/ma2024-02305068mtgabs.

Full text

Abstract:

The history of Atomic Layer Deposition (ALD) has been extensively researched in the VPHA-project (www.vph-ald.com/) initiated in 2013 by R. Puurunen [1]. It is commonly accepted that Atomic Layer Deposition (ALD) was conceived in the Baltic area as a unique ultrathin-film growth method based on the repeated, self-terminating gas-solid half-reactions of at least two volatile compounds on a solid substrate surface. Originally, in the 1960’s, the Russians Alekskovski and Kol'tsov [2]) named this method Molecular Layering and exactly 50 years ago, in 1974 the Finnish inventors Suntola and Antson [

APA, Harvard, Vancouver, ISO, and other styles

32

Poumeaud, François, Mathilde Morisseau, Luc Cabel, et al. "Abstract PS08-02: Efficacy of Sacituzumab-Govitecan (SG) post Trastuzumab-deruxtecan (T-DXd) and vice versa for HER2low advanced or metastatic breast cancer (MBC): a French multicentre retrospective study." Cancer Research 84, no. 9_Supplement (2024): PS08–02—PS08–02. http://dx.doi.org/10.1158/1538-7445.sabcs23-ps08-02.

Full text

Abstract:

Abstract Background: Based on ASCENT, TROPICS-02 and DESTINY-Breast04 trials, SG and T-DXd recently became approved for HER2low MBC. Since the payloads of both SG and T-DXd belong to the same cytotoxic class (topoisomerase-1 inhibitor), cross-resistance is a potential concern. However, no data is available on the efficacy of one antibody drug conjugate (ADC) after another and the best therapeutic sequence has not been evaluated yet. Methods: We conducted a retrospective study in 19 French comprehensive cancer centres. All patients (pts) with HR+ or HR- and HER2low MBC treated with SG followed,

APA, Harvard, Vancouver, ISO, and other styles

33

Browne, Iseult, Ronan McLaughlin, Catherine Weadick, et al. "Abstract PO5-02-04: Irish National Analysis of the Clinical and Economic impact of 21-gene Oncotype DX® testing in Early-Stage, 1-3 lymph node positive, Hormone Receptor positive (HR+), HER2-Negative (HER2-), Breast Cancer (BC)." Cancer Research 84, no. 9_Supplement (2024): PO5–02–04—PO5–02–04. http://dx.doi.org/10.1158/1538-7445.sabcs23-po5-02-04.

Full text

Abstract:

Abstract Background: The treatment landscape of HR+ BC is evolving, with a reduction in chemotherapy (CT) use because of Oncotype DX Recurrence Score® testing. Results from the RxPONDER trial suggest that adjuvant CT may benefit some premenopausal women with HR+, HER2- disease with 1-3 positive LN (N1), and a Recurrence Score® (RS) result of ≤25. Postmenopausal women with similar characteristics did not benefit from adjuvant CT. A previous analysis of the impact of Oncotype DX® testing in a N1 BC population from 2 Irish cancer centres identified a 55% reduction in CT use with savings of over €

APA, Harvard, Vancouver, ISO, and other styles

34

Ostinelli, Alexis, Pablo Mandó, Carolina Almada, et al. "Abstract PO4-16-07: Cyclin-dependent kinase inhibitor plus endocrine therapy in HR+/HER2- invasive breast cancer with bone marrow and pancytopenia: a new standard of care? Collaborative multicentric Argentinean real-world study (SUMA-02)." Cancer Research 84, no. 9_Supplement (2024): PO4–16–07—PO4–16–07. http://dx.doi.org/10.1158/1538-7445.sabcs23-po4-16-07.

Full text

Abstract:

Abstract Introduction Bone marrow involvement is a rare occurrence in patients with advanced breast cancer (ABC), and the prognosis in this context is generally poor. Prompt initiation of treatment to improve the patient's hematological status is crucial. However, this condition is often excluded from clinical trials, making it challenging to determine the effectiveness of new drugs. Limited data and evidence are available to guide treatment decisions, but guidelines recommend starting with chemotherapy for the need of a rapid response. This study aims to analyze the real-world efficacy of cyc

APA, Harvard, Vancouver, ISO, and other styles

35

Cani, Andi, Emily Dolce, Alissa Turnbull, et al. "Abstract P4-02-04: Serial monitoring of circulating tumor cells and circulating tumor DNA in metastatic lobular breast cancer identifies intra-tumor heterogeneity and precision and immuno-oncology biomarkers of therapeutic importance." Cancer Research 83, no. 5_Supplement (2023): P4–02–04—P4–02–04. http://dx.doi.org/10.1158/1538-7445.sabcs22-p4-02-04.

Full text

Abstract:

Abstract Clinical decisions on precision and immuno-oncology therapies are based on predictive biomarkers commonly obtained from a single metastatic biopsy or archived primary tumor tissue. Circulating genomic biomarkers offer a minimally invasive approach to monitor intra-patient tumor heterogeneity and detect in real-time the clinically-relevant evolving clonal architecture. Although currently underutilized, we hypothesize that single-cell DNA next generation sequencing (scNGS) of circulating tumor cells (CTC) is a particularly well-suited method to complement biomarker information obtained

APA, Harvard, Vancouver, ISO, and other styles

36

Heshin-Bekenstein, M., A. Ziv, N. Toplak, et al. "POS0258 SAFETY AND IMMUNOGENICITY OF BNT162b2 mRNA COVID-19 VACCINE AMONG ADOLESCENTS WITH RHEUMATIC DISEASES TREATED WITH IMMUNOMODULATORY MEDICATIONS." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 370.2–371. http://dx.doi.org/10.1136/annrheumdis-2022-eular.4691.

Full text

Abstract:

BackgroundAdolescents with juvenile-onset autoimmune inflammatory rheumatic diseases (AIIRD) could be at risk for disease flare secondary to SARS-CoV-2 infection or to withholding anti-inflammatory therapy. While vaccination can protect against COVID-19, safety and immunogenicity data regarding anti-SARS-CoV-2 vaccines among adolescents with AIIRD are limited.ObjectivesThis international, prospective, multicentre study evaluated the safety and immunogenicity of the BNT162b2 anti-SARS-CoV-2 vaccine among adolescents and young adults with juvenile-onset AIIRD, 80% of whom are on chronic immunomo

APA, Harvard, Vancouver, ISO, and other styles

37

Lee, Marcus, and Jules Cohen. "Abstract P4-05-24: Point mutations (PM), gene amplifications (GA) and variants of unknown significance (VUS) detected by next-generation sequencing (NGS) in a real-world sample of metastatic breast cancer (MBC)." Clinical Cancer Research 31, no. 12_Supplement (2025): P4–05–24—P4–05–24. https://doi.org/10.1158/1557-3265.sabcs24-p4-05-24.

Full text

Abstract:

Abstract Background: The management of MBC requires NGS of tissue biopsies or ctDNA. Certain changes in the tumor genome, predominantly PM in ESR1 and PIK3CA, are targetable with FDA-approved drugs. GA, with the notable exception of ERBB2, is a common but not actionable finding on NGS. Commercial NGS report amplification of multiple genes within a sample but do not always indicate they are amplified en bloc from the same chromosomal region or amplicon. We evaluated NGS results from MBC to (1) report the prevalence of PM across a real-world cohort; (2) organize individual GA within their respec

APA, Harvard, Vancouver, ISO, and other styles

38

Peng, PeiJian, Xiao-Lu Xu, Jin-Cai Zhong, et al. "Abstract PO3-05-10: Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multi-center, open-label, single-arm, phase II study." Cancer Research 84, no. 9_Supplement (2024): PO3–05–10—PO3–05–10. http://dx.doi.org/10.1158/1538-7445.sabcs23-po3-05-10.

Full text

Abstract:

Abstract Background: Eribulin is a halichondrin non-taxane inhibitor of microtubule dynamics approved in China for advanced breast cancer patients who have received at least two prior chemotherapy treatments. The combination of eribulin and gemcitabine has demonstrated a similar progression-free survival (PFS) benefit as paclitaxel plus gemcitabine, with less neurotoxicity, for patients with MBC who have not received prior cytotoxic chemotherapy. However, the effect of eribulin plus gemcitabine on PFS in second line or beyond remains unclear. Methods: This open-label, single-arm, phase II stud

APA, Harvard, Vancouver, ISO, and other styles

39

Bottosso, Michele, Renata Lazari Sandoval, Benjamin Verret, et al. "Abstract P5-02-18: HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome." Cancer Research 83, no. 5_Supplement (2023): P5–02–18—P5–02–18. http://dx.doi.org/10.1158/1538-7445.sabcs22-p5-02-18.

Full text

Abstract:

Abstract Background: Breast cancer (BC) is the most common tumor in women with Li-Fraumeni syndrome (LFS), with a cumulative incidence of 85% by the age of 60 years. However, LFS-related BC characteristics are still underexplored since most data derive from small retrospective cohorts. A variable enrichment in HER2-positivity (ranging from 34 to 80%) has been reported, but information regarding the response to anti-HER2 treatments are currently lacking. Moreover, data regarding the new emerging category of HER2-low are missing. Methods: Invasive BCs diagnosed in patients (pts) with TP53 germli

APA, Harvard, Vancouver, ISO, and other styles

40

O'Shaughnessy, Joyce, Reva Basho, Maryam Lustberg, et al. "Abstract PO4-17-02: A multicenter, prospective, observational study of patients receiving trastuzumab deruxtecan for the treatment of HER2-positive and HER2-low unresectable and/or metastatic breast cancer: DESTINY-Breast-RESPOND." Cancer Research 84, no. 9_Supplement (2024): PO4–17–02—PO4–17–02. http://dx.doi.org/10.1158/1538-7445.sabcs23-po4-17-02.

Full text

Abstract:

Abstract Background: Approximately 20% of breast cancer (BC) cases are human epidermal growth factor receptor 2-positive (HER2+; immunohistochemistry [IHC] 3+, IHC 2+/in-situ hybridization [ISH]+), and up to ~50% of patients with primary or metastatic BC (mBC) have HER2-low tumors (IHC 1+, IHC 2+/ISH−), a new therapeutically targetable subset of BC. Trastuzumab deruxtecan (T-DXd) is a HER2-directed antibody-drug conjugate approved in the USA, EU, and other countries for the treatment of adult patients with unresectable or metastatic HER2+ BC who have received a prior anti-HER2-based regimen, o

APA, Harvard, Vancouver, ISO, and other styles

41

Danciu, Oana C., Kent Hoskins, Jennifer Weiss, et al. "Abstract P4-01-38: A single arm phase II trial of Palbociclib in combination with Tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer." Cancer Research 83, no. 5_Supplement (2023): P4–01–38—P4–01–38. http://dx.doi.org/10.1158/1538-7445.sabcs22-p4-01-38.

Full text

Abstract:

Abstract Background: Palbociclib is a CDK4/6 inhibitor used to treat metastatic hormone receptor-positive (HR+) breast cancer (MBC) in combination with endocrine therapy. Tamoxifen is an effective treatment for HR+ MBC, with different toxicity profile compared with aromatase inhibitors (AI) and fulvestrant. Preclinical data demonstrated synergy for the combination of tamoxifen and palbociclib, being effective in a model of acquired tamoxifen resistance. Methods: We conducted a non-randomized, open-label, single-arm, multicenter, phase II trial of palbociclib in combination with tamoxifen in pa

APA, Harvard, Vancouver, ISO, and other styles

42

Prat, Aleix, Benedetta Conte, Fara Brasó-Maristany, et al. "Abstract PO1-06-02: Solti-1716 TATEN phase II trial: Targeting non-Luminal disease by PAM50 with pembrolizumab and paclitaxel in Hormone Receptor-positive/HER2-negative advanced breast cancer (ABC)." Cancer Research 84, no. 9_Supplement (2024): PO1–06–02—PO1–06–02. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-06-02.

Full text

Abstract:

Abstract Background Within HR+/HER2-negative breast cancer, PAM50 non-luminal tumors (HER2-enriched [HER2-E] and Basal-like) have higher expression of proliferation and immune-related genes and tumor infiltrating lymphocytes and might benefit from immunotherapy. Here, we report the efficacy, safety, and correlative analysis data of the TATEN trial, the first study designed to evaluate pembrolizumab and paclitaxel in HR+/HER2-negative, PAM50 non-luminal, ABC. Methods TATEN trial (NCT04251169) is a single-arm, multicenter, phase II study evaluating pembrolizumab in combination with paclitaxel in

APA, Harvard, Vancouver, ISO, and other styles

43

Tasoulis, Marios Konstantinos, Romney Pope, Tanja Gagliardi, et al. "Abstract PD16-03: Use of post-neoadjuvant chemotherapy image-guided breast vacuum assisted biopsy to predict residual cancer in exceptional responders: A prospective cohort study." Cancer Research 83, no. 5_Supplement (2023): PD16–03—PD16–03. http://dx.doi.org/10.1158/1538-7445.sabcs22-pd16-03.

Full text

Abstract:

Abstract Background: Post-neoadjuvant chemotherapy (NAC) image-guided biopsy of the residual imaging abnormality/tumor bed is increasingly used to assess residual disease in the breast and potentially identify exceptional responders who may not require surgical intervention. Previous studies have shown variable results on the diagnostic performance of this technique. The aim of this analysis was to assess the accuracy of post-NAC, image-guided vacuum assisted biopsy (VAB) to predict residual disease in the breast using a standardized assessment protocol. The findings could help further support

APA, Harvard, Vancouver, ISO, and other styles

44

Fontalvo Díaz, Norlys Margoth, Boris Marcelo Torres Zavala, and Jorge Washington Vélez Páez. "Preeclampsia-eclampsia como factor de riesgo para el desarrollo de enfermedad renal crónica." Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante 10, no. 2 (2022): 90–96. http://dx.doi.org/10.56867/31.

Full text

Abstract:

Introducción: La preeclampsia-eclampsia es un trastorno sistémico del embarazo prevalente caracterizado por hipertensión y proteinuria, un signo de disfunción renal. Se sabe relativamente poco sobre sus efectos a largo plazo en el riñón ya sea en términos de daño físico medido por albuminuria o proteinuria, desarrollo de hipertensión arterial crónica, deterioro funcional medido por la reducción de tasa de filtración glomerular o insuficiencia renal crónica (ERC). Métodos: En el presente estudio analítico y retrospectivo se tomaron los datos de las historias clínicas de pacientes con antecedent

APA, Harvard, Vancouver, ISO, and other styles

45

Rico-Fontalvo, Jorge, Rodrigo Daza-Arnedo, Tomas Rodríguez-Yanez, et al. "Obesidad y enfermedad renal crónica. Una mirada desde los mecanismos fisiopatológicos." Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante 10, no. 2 (2022): 97–107. http://dx.doi.org/10.56867/32.

Full text

Abstract:

Introducción: La enfermedad renal crónica asociada a la obesidad (ERC-AO) es una enfermedad con aumento en la prevalencia en las últimas décadas. Se caracteriza por un exceso de desequilibrios hormonales adipocíticos (adipoquinas), desregulación del sistema de equilibrio energético y desequilibrios en la homeostasis metabólica. Propósito de la revisión: El objetivo de la revisión es delinear el papel de los diferentes mecanismos fisiopatológicos para el desarrollo de enfermedad renal funcional o anatómica en pacientes con obesidad. Buscamos reportes actualizados en donde se incluye los resulta

APA, Harvard, Vancouver, ISO, and other styles

46

Ferreira, Benedito De Jesus Pinheiro. "Educação e mídias digitais: a necessária síntese da contradição valor de uso/valor de troca (Education and digital media: the necessary synthesis of the use-value / exchange value contradiction)." Revista Eletrônica de Educação 14 (March 3, 2020): 3773071. http://dx.doi.org/10.14244/198271993773.

Full text

Abstract:

Use value refers to the usefulness of social productions in the sense of the increasingly effective fulfillment of human needs, as well as the production of new, ever richer, more human needs. However, in a society oriented by the logic of capital, thus oriented to the production of goods for exchange (commodities), the use value will always be determined, though not unilaterally, by the fact that it is in indissoluble unity with the exchange value, which leads, as a rule, to the secondary consideration of supplying/ production of needs in favor of the increased production of plus-value, the s

APA, Harvard, Vancouver, ISO, and other styles

47

Kojo, Kosuke. "Methods to Enhance Accessibility of Japanese Medical Literature in English Journals." JMA Journal 7, no. 4 (2024): 461–70. https://doi.org/10.31662/jmaj.2024-0140.

Full text

Abstract:

Title <strong>Methods to Enhance Accessibility of Japanese Medical Literature in English Journals</strong> Abstract To address the challenges of accurately citing Japanese medical literature in English journals, the essential guidelines “Citing Medicine” by the National Library of Medicine were reviewed, focusing on practical adjustments to enhance accessibility. Key proposals include the use of persistent identifiers (Digital Object Identifier, PubMed Identifier, and International Standard Book Number), proper citation of online content, and the inclusion of romanized Japanese art

APA, Harvard, Vancouver, ISO, and other styles

48

Sousa-Lopes, Bruno De, and Nayane Alves da Silva. "Entomologia na escola: o que os estudantes pensam sobre os insetos e como utilizá-los como recurso didático? (Entomology in the school: what do students think about insects and how to use them as a didactic resource?)." Revista Eletrônica de Educação 14 (April 13, 2020): 3300078. http://dx.doi.org/10.14244/198271993300.

Full text

Abstract:

Insects represent a relevant didactic resource to work with artistic skills, concepts, attitudes and values in the Science teaching because they are diversified in forms and colors, and because they have different life styles. However, there are relatively few reports of experience with evidence of their importance as a didactic resource. In this sense, our main aims were to describe and analyze: (1) the perceptions of seventh-year elementary school students of a public school in Uberlândia-MG, Brazil, about insects; and (2) a didactic sequence in which insects are used to work concepts, artis

APA, Harvard, Vancouver, ISO, and other styles

49

Magalhães, Priscila Giselli Silva, Ruth Daisy Capistrano de Souza, Layana Mayumi Murakami Kawakami, and Rafaela Moreira de Souza e Silva. "Aplicação do plano de desenvolvimento individual para uma aluna com deficiência visual (Application of the individual development plan for a visually impaired student)." Revista Eletrônica de Educação 15 (November 30, 2021): e5029053. http://dx.doi.org/10.14244/198271995029.

Full text

Abstract:

e5029053The school inclusion of students with visual impairment faces challenges regarding pedagogical evaluation in an individualized way, and in relation to an efficient pedagogical follow-up of the same. One proposal which has sew highlighted in the school environment is the Individual Development Plan (PDI) which is a form of pedagogical assessment for students with disabilities who attend the Multifunctional Resource Room (MRR). This article aimed to analyze the PDI in the pedagogical evaluation of a visually impaired student and originated from a research with a case study methodologyin

APA, Harvard, Vancouver, ISO, and other styles

50

Saroj, Kumar Sah, Kaur Amandeep, and S.H.Wani. "NANOBIOTECHNOLOGY: CHANGING HORIZONS OF SCIENCE." Biolife 2, no. 3 (2022): 905–16. https://doi.org/10.5281/zenodo.7223568.

Full text

Abstract:

<strong>ABSTRACT</strong> Scientists worldwide are continuing to discover unique properties of every day materials at the submicrometer scale. This size domain is better known as nanometer domain and technology concerned with this is known as nanotechnology that involves working with particles at nano level. One of the most important emerging fields of science in this century is Nanotechnology. It deals with designing, construction, investigation and utilization of systems at the nanoscale. The interface between nanotechnology and biotechnology is nanobiotechnology, which exploits nanotechnolo

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!